Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
Document Type
Article
Publication Date
4-15-2016
Journal Title
Clinical cancer research : an official journal of the American Association for Cancer Research
MeSH Headings
Adolescent, Adult, Aminoglycosides, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Child, Child, Preschool, Female, Follow-Up Studies, Gemtuzumab, Gene Duplication, Hematopoietic Stem Cell Transplantation, Humans, Infant, Infant, Newborn, Leukemia, Myeloid, Acute, Male, Prognosis, Recurrence, Treatment Outcome, Young Adult, fms-Like Tyrosine Kinase 3
Abstract
PURPOSE: Gemtuzumab ozogamicin (GO), a calicheamicin-conjugated mAb against CD33, has been used in the treatment of acute myeloid leukemia (AML). We evaluated the impact of the addition of GO to standard chemotherapy and hematopoietic stem cell transplant (HCT) in patients withFLT3/ITD.
EXPERIMENTAL DESIGN: We analyzed children withFLT3/ITD-positive AML (n= 183) treated on two consecutive Children's Oncology Group AML trials (NCT00070174andNCT00372593). Outcomes were assessed forFLT3/ITD patients receiving standard chemotherapy with or without GO (GO vs. No-GO, respectively), and the impact of consolidation HCT for high-riskFLT3/ITD patients [highFLT3/ITD allelic ratio (ITD-AR)].
RESULTS: For allFLT3/ITD patients, complete remission (CR) rates for the GO versus No-GO cohorts were identical (64% vs. 64%;P= 0.98). Relapse rate (RR) after initial CR was 37% for GO recipients versus 59% for No-GO recipients (P= 0.02), disease-free survival (DFS) was similar (47% vs. 41%;P= 0.45), with higher treatment-related mortality (TRM) in GO recipients (16% vs. 0%;P= 0.008). Among high-riskFLT3/ITD patients with high ITD-AR, those who received HCT in first CR with prior exposure to GO had a significant reduction in RR (15% vs. 53%;P= 0.007), with a corresponding DFS of 65% versus 40% (P= 0.08), and higher TRM (19% vs. 7%;P= 0.08).
CONCLUSIONS: CD33 targeting with HCT consolidation may be an important therapeutic strategy in high-riskFLT3/ITD AML and its efficacy and associated toxicity warrant further investigation.
ISSN
1078-0432
First Page
1951
Last Page
1957
Recommended Citation
Tarlock, Katherine; Alonzo, Todd A; Gerbing, Robert B; Raimondi, Susana C; Hirsch, Betsy A; Sung, Lillian; Pollard, Jessica A; Aplenc, Richard; Loken, Michael R; Gamis, Alan S; and Meshinchi, Soheil, "Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group." (2016). Maine Medical Center. 1610.
https://knowledgeconnection.mainehealth.org/mmc/1610
